Related Experiment Video
Updated: Jun 13, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
From Pathway Tracing to Actionable Targets: Integrative Mendelian Randomization and Experimental Triangulation Map
Xinqi Wang1, Haoyu Wang1,2,3, Siyuan Hu1
1Department of Obstetrics and Gynecology, Pelvic Floor Research Centre of Hubei Province, Renmin Hospital of Wuhan University, No. 238 Jiefang Road, Wuchang District, Wuhan 430060, China.
International Journal of Molecular Sciences
|June 12, 2026
Summary
This study reveals how specific metabolic pathways and drug targets influence different ovarian cancer types. It identifies key metabolic drivers and actionable targets for ovarian cancer, offering a path for new treatments.
Area of Science:
- Metabolic pathways
- Genetics
- Ovarian cancer research
Background:
- Ovarian cancer (OC) has diverse subtypes with unique characteristics.
- Understanding metabolic differences is crucial for targeted therapies.
Purpose of the Study:
- To map histotype-stratified metabolic pathways in ovarian cancer.
- To connect these pathways to drug targets, creating a risk chain.
- To validate findings experimentally.
Main Methods:
- Used a multi-stage Mendelian randomization (MR) framework with Integrative Epidemiology Unit (IEU) OpenGWAS data.
- Screened 1400 plasma metabolites against ovarian cancer subtypes.
- Performed cis drug-target MR and integrated triangulation, colocalization, and mediation analyses.
Main Results:
- Identified amino-acid nitrogen and central-carbon metabolism as key areas.
- Found specific metabolites linked to different ovarian cancer histotypes (e.g., alanine and LGSOC, glutamate and endometrioid OC).
- Prioritized PPARG as protective and ABCC8/KCNJ11 as risk-increasing for invasive mucinous ovarian cancer (IMOC), linked via lactate.
Conclusions:
- An integrative MR framework successfully delineated histotype-specific metabolic drivers in ovarian cancer.
- Linked metabolic drivers to actionable drug targets, establishing a target-metabolic node-histotype risk chain.
- Provided a roadmap for translating genetic discoveries into mechanistic and therapeutic validation for ovarian cancer.
